Bethany Sleckman

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

Daniel V.T. Catenacci, Melissa R. Junttila, Theodore Karrison et al. · Journal of Clinical Oncology · 2015 · 544 citations

Medicine, Oncology, Pharmacology +17

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

Ronald B. Natale, David Bodkin, Ramaswamy Govindan et al. · Journal of Clinical Oncology · 2009 · 226 citations · Full text

Medicine, Oncology, Pharmacology +17

ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial

Ronald B. Natale, David Bodkin, Ramaswamy Govindan et al. · Journal of Clinical Oncology · 2006 · 109 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Epstein-Barr virus in Hodgkin's disease: correlation of risk factors and disease characteristics with molecular evidence of viral infection.

Bethany Sleckman, Peter Mauch, Richard F. Ambinder et al. · PubMed · 1998 · 54 citations

Veterinary Medicine, Infectious Diseases, Pathology +16